Navigation Links
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
Date:1/31/2008

mpact, primarily due to increased sales in infant formula and

broad-based growth in Asia and Latin America.

ConvaTec

-- Worldwide ConvaTec sales increased 11%, including a 7% favorable

foreign exchange impact, to $323 million in the fourth quarter of 2007

from $291 million in the same period in 2006. Sales of wound

therapeutic products increased 11%, including a 7% favorable foreign

exchange impact, to $136 million in the fourth quarter of 2007 from

$123 million in the same period in 2006, primarily due to continued

growth of AQUACEL(R).

2008 GUIDANCE

Bristol-Myers Squibb revises its 2008 earnings guidance for fully diluted earnings per share from continuing operations on a GAAP basis to be between $1.36 and $1.46 from $1.44 to $1.54, primarily reflecting the impact from the sale of the Medical Imaging business. The revised GAAP guidance includes estimated charges of approximately $500 million related to implementation of the Productivity Transformation Initiative, which will be dependent on timing of implementation and accounting treatment.

The company also revises its 2008 fully diluted earnings per share from continuing operations guidance on a non-GAAP basis to be between $1.60 and $1.70 from $1.65 to $1.75, primarily reflecting the impact of the Medical Imaging divestiture. The non-GAAP guidance excludes specified items as discussed under "Use of Non-GAAP Financial Information." Details reconciling adjusted non-GAAP amounts with the amounts reflecting specified items are provided in supplemental materials available on the company's website.

Further, the 2008 guidance excludes other specified items such as gains or losses from sale of businesses and product lines; from sale of equity investments and from discontinuations of operations; restructuring items that meet the requirements of SFAS 112 for severance and SFAS 146 for other exit costs; accelerated deprec
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine news :

1. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
2. Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
3. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
4. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
5. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
6. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
7. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
8. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
9. Bristol-Myers Squibb Announces Dividend
10. P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company
11. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dennis Thompson HealthDay ... -- Ebola,s entrance into the United States -- along ... mumps outbreak -- have highlighted cracks in the nation,s ... new health policy report released Thursday. Half of ... respond to infectious disease outbreaks. That was the main ...
(Date:12/19/2014)... 2014 Hands On Mobile Spa, has announced ... Spa On Wheels has been transformed into a utopia for ... world seems to disappear. The Virtual Tour showcases the beauty ... parties, corporate events and more. , The Virtual Tour shows ... which is actually an overhauled Winnebago. Marla Kaplan-Pelle, Director states ...
(Date:12/19/2014)... Wisconsin (PRWEB) December 19, 2014 After ... music performer is again returning to the stage to ... her husband for concert performances, and the successful tour ... was originally announced. , Visit Ticketability.com ... the newly-announced Detroit shows at fair prices. , Music ...
(Date:12/19/2014)... (HealthDay News) -- A new study suggests a possible ... hot flashes and night sweats -- and higher rates ... are common during menopause, affecting about 60 percent of ... after menopause, since they then face a higher risk ... women who exhibit moderate or severe menopausal symptoms are ...
(Date:12/19/2014)... Prostaglandin analogue eye drops -- a common form of ... loss in patients with the eye disease, a new ... of the Moorfields Eye Hospital and UCL Institute of ... people newly diagnosed with open-angle glaucoma -- the most ... leading causes of blindness. About 45 million people ...
Breaking Medicine News(10 mins):Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2
... 2 (HealthDay News) -- Babies born to women who smoke ... have a congenital heart defect than are the offspring of ... increased risk ranged from 20 percent to 70 percent, varying ... that obstruct the flow of blood from the right side ...
... long-term alcohol abuse is detrimental to memory function and ... published in Age and Ageing by Oxford ... consumption may decrease the risk of cognitive decline or ... the prevalence of alcohol-related dementia to be about 10% ...
... 18th Conference on Retroviruses and Opportunistic Infections is ... from February 27 through March 2. Day three of ... presentations from scientists supported by the National Institute of ... Institutes of Health. iPrEx Update , ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, March 1 ... announcement Monday that researchers reconfigured immune cells so that they became ... But they say the jury is out on whether the ... is ultimately a cure or what,s called a "functional cure" -- ...
... years are a critical period for addressing weight-related ... University of Illinois at Chicago. Among young children, ... is highest among black and Hispanic children. ... from the U.S. Department of Agriculture to integrate ...
... Eye Institute (NEI) and Food and Drug Administration (FDA) ... endpoints for clinical trials of visual prostheses will be ... visual fields and contrast sensitivity. These assessments may provide ... Today, functional vision outcomes such as ...
Cached Medicine News:Health News:Smoking During Early Pregnancy May Put Baby's Heart at Risk 2Health News:Research suggests alcohol consumption helps stave off dementia 2Health News:Research suggests alcohol consumption helps stave off dementia 3Health News:CROI -- Day 3: Selected highlights of NIH-supported research 2Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 2Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 3Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 4Health News:$1 million USDA grant aims to reduce obesity in preschoolers 2Health News:Visual prostheses: Symposium to explore combining functional endpoints 2
(Date:12/17/2014)... Ga. and RALEIGH, N.C. ... Trial Marketing Communications, LLC (CTMC), and Integrated Clinical ... patient recruitment and retention for clinical trials announce ... Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS will ... retention services to pharmaceutical, biotechnology and medical device ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "MEMS Gyroscopes Analog ... Analysis" report to their offering. ... gyroscopes for tactical grade applications made a lot ... term of reliability. They are now accepted in ...
(Date:12/15/2014)... --Research and Markets , ... announced the addition of the "Cardiac Guidewires - ... offering. Global Guidewires sector is projected to reach ... accounts for nearly 35% (2015) of the ... approximately 25% (2018). Asia-Pacific is ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4
... Broadest, Most Comprehensive Survey Provides New Benchmark on MRSA,in Healthcare ... today by APIC: , , WHAT:, ... Methicillin-resistant, Staphylococcus aureus (MRSA), ... in U.S. healthcare facilities., -- MRSA ...
... LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc.,(OTCBB:NRGX) ... issue,of the journal The Lancet of positive results ... disease and the first report of,direct gene transfer ... adult,neurodegenerative disease., The open label Phase 1 study, ...
Cached Medicine Technology:Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6
... Osteon Bone Graft Substitutes a natural alternative ... cadaver bone, but such grafts may introduce ... transmission. Interpore Cross has developed the Pro ... address these needs, offering surgeons a broad ...
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Beckman-Weitlaner retractor, blunt, with hinged arms, 6 1/2"....
Halle bone curette, 8 1/4, oval, malleable shaft, 4 mm wide....
Medicine Products: